Case report: therapeutic monitoring of vancomycin in an acute liver failure patient with anuria under high-flow continuous hemodiafiltration
- PMID: 37122008
- PMCID: PMC10150540
- DOI: 10.1186/s40780-023-00283-0
Case report: therapeutic monitoring of vancomycin in an acute liver failure patient with anuria under high-flow continuous hemodiafiltration
Abstract
Background: High-flow continuous hemodiafiltration (HF-CHDF) combines diffusive and convective solute removal and is employed for artificial liver adjuvant therapy. However, there is no report on dosage planning of vancomycin (VCM) in patients with acute liver failure under HF-CHDF.
Case presentation: A 20-year-old woman (154 cm tall, weighing 50 kg) was transferred to the intensive care unit (ICU) with acute liver failure associated with autoimmune liver disease. On the following day, HF-CHDF was started due to elevated plasma ammonia concentration. On ICU day 8, VCM was started for suspected pneumonia and meningitis (30 mg/kg loading dose, then 20 mg/kg every 12 hrs). However, on ICU day 10, VCM blood concentration was under the limit of detection (< 3.0 μg/mL) and the patient developed anuria. The VCM dose was increased to 20 mg/kg every 6 hrs. Calculation with a one-compartment model using the HF-CHDF blood flow rate as a surrogate for VCM clearance, together with hematocrit and protein binding ratio, predicted a trough VCM blood concentration of 15 μg/mL. The observed concentration was about 12 μg/mL. The difference may represent non-HF-CHDF clearance. Finally, living donor liver transplantation was performed.
Conclusion: We report an acute liver failure patient with anuria under HF-CHDF in whom VCM administration failed to produce an effective blood concentration, likely due to HF-CHDF-enhanced clearance. VCM dosage adjustment proved successful, and was confirmed by calculation using a one-compartment model.
Keywords: Anuric; High flow continuous hemodiafiltration; Therapeutic drug monitoring; Vancomycin.
© 2023. The Author(s).
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures


Similar articles
-
Population Pharmacokinetics of Vancomycin Under Continuous Renal Replacement Therapy Using a Polymethylmethacrylate Hemofilter.Ther Drug Monit. 2020 Jun;42(3):452-459. doi: 10.1097/FTD.0000000000000721. Ther Drug Monit. 2020. PMID: 31913865
-
Contribution of diafiltration and adsorption to vancomycin clearance in a continuous hemodiafiltration circuit model in vitro.Artif Organs. 2022 Jun;46(6):1086-1096. doi: 10.1111/aor.14178. Epub 2022 Feb 6. Artif Organs. 2022. PMID: 35048387
-
Vancomycin pharmacokinetics in critically ill patients receiving continuous haemodiafiltration with a polyethyleneimine-coated polyacrylonitrile membrane.J Clin Pharm Ther. 2020 Oct;45(5):1143-1148. doi: 10.1111/jcpt.13197. Epub 2020 Jun 4. J Clin Pharm Ther. 2020. PMID: 32497268
-
[Indications for and clinical efficacy of continuous hemodiafiltration (CHDF) for severe acute pancreatitis].Nihon Rinsho. 2004 Nov;62(11):2094-100. Nihon Rinsho. 2004. PMID: 15552894 Review. Japanese.
-
Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock.Contrib Nephrol. 2007;156:365-70. doi: 10.1159/000102127. Contrib Nephrol. 2007. PMID: 17464147 Review.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous